ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen HMGA2.

OBJECTIVES

Estrogen is proven to promote the malignant behaviors of many cancers its receptors. Estrogen receptor alfa 36 (ER-α36) is a newly identified isoform of estrogen receptor alfa (ER-α), the role of ER-α36 in regulating the effects of estrogen and its potential impact on human cervical cancer is poorly understood.

METHODS

Immunohistochemistry staining was used to evaluate the expression of ER-α36, estrogen receptor alfa 66 (ER-α66) and their prognostic values in cervical cancer. The effects of ER-α36 and ER-α66 on the proliferation and metastasis of cervical cancer were measured . A xenograft tumor assay was used to study the tumorigenesis role of ER-α36 . Furthermore, the functional gene at the downstream of ER-α36 was obtained next-generation sequencing, and the biological functions of high mobility group A2 (HMGA2) in cervical cancer cells were investigated .

RESULTS

ER-α36 was over-expressed in cervical cancer tissues and elevated ER-α36 expression was associated with poor prognosis in cervical cancer patients. High expression of ER-α36 promoted the proliferation, invasion and metastasis of cervical cancer cells mediated by estrogen, while silencing ER-α36 had the opposite effects. Further research showed that HMGA2 was a downstream target of ER-α36 in cervical cancer cells. The oncogenic effect of ER-α36 was attenuated after HMGA2 knockdown.

CONCLUSIONS

High expression of ER-α36 was correlated with a poor prognosis in cervical cancer by regulating HMGA2. ER-α36 could be a prognostic biomarker and a target for cervical cancer treatment.